News | April 03, 2026
Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
Its a major breakthrough for women’s ovarian cancer care in Europe
Its a major breakthrough for women’s ovarian cancer care in Europe
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The presentations underscore the company’s deep expertise in dermatology and immunology
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
Subscribe To Our Newsletter & Stay Updated
